9 Results

People

  1. Schoder
    Schoder
  2. Moskowitz
    Moskowitz
  3. Moskowitz
    Moskowitz
  4. Horwitz
    Horwitz
  5. Noy
    Noy
  6. Zelenetz
    Zelenetz
  7. Hamlin
    Hamlin
  8. Matasar
    Matasar
  9. Palomba
    Palomba
  10. Gerecitano
    Gerecitano

Groups

  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. Hematologic Malignancies, Division of (9)
  4. Lymphoma (9)
  5. Molecular Imaging and Therapy Service (9)
  6. Radiology, Department of (9)
  7. Population Sciences Research Program (5)
  8. Survivorship Research (4)
  9. Advanced Practice Providers (3)
  10. Bone Marrow Transplant (3)
  1. "Center for Hematologic Malignancies"
  2. "Lymphoma"
  3. "Molecular Imaging and Therapy Service"
  4. "2016"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. Hematologic Malignancies, Division of (9)
  4. Lymphoma (9)
  5. Molecular Imaging and Therapy Service (9)
  6. Radiology, Department of (9)

More Groups

People
  1. Heiko Schoder (8)
  2. Alison Moskowitz (6)
  3. Craig Moskowitz (6)
  4. Andrew Zelenetz (5)
  5. Ariela Noy (5)
  6. David Straus (5)

More People

Years
  1. 2016 (9)
Publications
  1. Blood (4)
  2. Haematologica (2)
  3. Journal of Clinical Oncology (2)
  4. Journal of Nuclear Medicine (1)
Publishers
  1. American Society of Hematology (4)
  2. American Society of Clinical Oncology (2)
  3. Ferrata Storti Foundation (2)
  4. Society of Nuclear Medicine (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy
    Meeting Abstract

    Gavane, S. C.; Ito, K.; Moskowitz, C. H.; Moskowitz, A. J.; Schoder, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303
    Meeting Abstract

    Wilson, W. H.; Sin-Ho, J.; Pitcher, B. N.; Hsi, E. D.; Friedberg, J.; Cheson, B.; Bartlett, N. L.; Smith, S.; Johnston, N. W.; Kahl, B. S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
    Journal Article

    Press, O. W.; Li, H.; Schöder, H.; Straus, D. J.; Moskowitz, C. H.; LeBlanc, M.; Rimsza, L. M.; Bartlett, N. L.; Evens, A. M.; Mittra, E. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save